The rise of impressive generative AI models like OpenAI’s Sora is sparking questions about how intellectual property law will need to adapt. The main areas of disruption include determining ownership of IP created by AI systems, as current laws only recognize human “authors” and “inventors.” While Sora and similar AI models produce high-quality outputs, they are still limited in their true understanding and may just be highly sophisticated imitations.

But how will the real transformative impact of AI come about, and what implications might this have for intellectual property law? 

Watch our video: Sora and AI: Who Really Owns AI Creations?

Jump to:

The Disruptive Potential of Generative AI in Intellectual Property Law

The Limits of Generative AI and the True Disruptive Potential

Adapting Intellectual Property Laws to the Era of AI-Driven Innovation

Closing Comments

The Disruptive Potential of Generative AI in Intellectual Property Law

OpenAI’s Sora software, a text-to-video generative AI model, recently made headlines showing a series of 1-paragraph prompts and some high-quality footage generated based on those prompts. It is a rightfully impressive showing, but it’s still too early to identify how IP law will be disrupted by generative AI.

The first area of possible disruption is who (if anyone) owns the rights to a work or an invention created by AI?  The US Constitution reserves copyrights and patents to “Authors and Inventors,” which thus far has been interpreted as limited only to human beings.  There are similar provisions in, for example, the European Patent Convention. As recently as the “monkey selfie” case (finally resolved in 2018), where a photographer left a camera out for a monkey to play with and then advocacy groups tried to claim copyright of the photograph on behalf of the monkey (the photographer also unsuccessfully tried to claim copyright), limiting authorship and inventorship to humans was not particularly in dispute in the legal world. There simply had not been any reason to alter the fundamental rationale of IP protection: in exchange for the hard work of creating the invention or the work and to incentivize this hard work, the creator receives a limited monopoly over monetizing it. 

With generative AI like Sora, however, it is now possible to reward a person’s (rather, peoples’) hard work in setting up the model that created the invention or the work.  For example, GPT-3 required 45 terabytes of training data, which cost several million dollars and uncounted person-hours of time and expertise. This is a significant investment, which if it can create a sufficient benefit to society, should be rewarded by changing IP law to incentivize it.

This is not an open-and-shut case.  Sora, and other generative AI, is an expensive tool for creating limited outputs.  Creating and operating a generative AI like Sora is a non-trivial exercise, with millions of dollars and person-hours devoted to collecting, curating, and then supervising any AI’s interaction with its training data. AI-assisted creation is and will be the provenance of large corporations that can foot that bill, or else services like Patsnap which specifically offer AI functionality to subscribers. The classic garage inventor or independent filmmaker will not have access to AI. A modern George Lucas could not use AI to make Star Wars.  Also, garbage in-garbage out is still true, and the quality of the AI’s training and interaction can be variable (as shown recently by Google), even with the best intentions.

The Limits of Generative AI and the True Disruptive Potential

My own experiments with generating prompts shows that the AI is always returning something that doesn’t—quite—match what I had in mind when I wrote the prompt. The technology is still in its infancy and may end like 1950s-era predictions of nuclear-powered cars and frequent commercial space travel by, to pick one example, the year 2001. It is not a sure thing that AI will reach the level of quality that its proponents are suggesting.

More importantly, even AIs that “understand” their field really don’t.

Just as computers swiftly execute repetitive tasks to produce complex outputs, AI engages in iterative pattern-matching and sorting to determine—admittedly, complex–associations. In the terms of the classic syllogism, AI does not understand that Socrates is mortal because mortality is an inherent attribute of humans, it has merely identified that there is an association between data labelled as a “human,” and data labelled “mortal.” This is how AIs frequently suffer “hallucinations” in which they present things which simply are not true. Data labelled “cat” is also associated with “mortal,” even where CAT cable or Navy catapults or other, non-feline uses of the word are encountered.

In addition, sometimes there is not an association to reproduce so that a normal run of an image-generating AI like Stable Diffusion produces many images that are not kept after human review—figures have misshapen faces or anatomical impossibilities created by the AI. In the world of litigation, multiple attorneys have been sanctioned after filing ChatGPT-drafted legal briefs which cited cases which simply don’t exist. 

In the case of Sora, despite some commentators being impressed by the AI “understanding” cinematic language, it really does not. AIs like Sora are inextricably tied to their training data and they more-or-less reproduce a “best fit” imitation of the associations detected in that data. Assuming Open AI trained Sora on competently shot and directed video (not on the entire corpus of YouTube or TikTok), it would be surprising if it didn’t show competent camera work. Should IP law upend its underlying assumptions to incentivize mere imitation? While it is tempting to imagine that AI will continue advancing based on its “understanding” of the world, it would be a mistake to attribute abilities that AIs, by design, simply do not have.

The second, and most long-lasting, area of disruption will come as inventors and practitioners leverage AI to enhance their own processes. This is where the true disruption will occur, and it will organically arise from the practitioners as new use cases for the pattern-matching and associations are found. In the 1940s, a “computer” was a person, often a woman with significant math skills but few job prospects to make use of them. By the end of World War 2, primitive electronic computers were in use to, for example, decode German Enigma messages. By 1976, the Cray-1 supercomputer was the size of a closet and used an 80 MHz processor and a little more than 8 MB of RAM (simplified for comparison’s sake).  By 2024, most people carry around in their pockets a device with multiple gigahertz processors and RAM, 1000x improvements. A user looking at a Cray might think through miniaturization and Moore’s law and determine some of the use cases of modern smartphones, but simply could not imagine all the intersections of cameras, video, sensors, etc. that have come to pass.

Adapting Intellectual Property Laws to the Era of AI-Driven Innovation

But a few things are clear:  AI’s ability to sort and classify, and then extrapolate based on those classifications to generate new material, will give new inventors and patent-seekers the ability to iterate on hundreds or even thousands of alternatives to find novelty, or to invent around competitors. Adding AI to existing use cases (vehicle sensors, for one), will also be areas of invention. It’s entirely possible that patent law will need to revisit the Alice decision in light of the integration of AI into business.

“Disruption” will be the word of the day.  The unfolding spectacle of its impact across industries and where exactly that disruption will take place, will be fascinating to watch.

Closing Comments:

The path forward may not be straightforward, but the journey promises to be a captivating one, with the full impact of AI’s disruption on the IP landscape yet to be fully realized. As stakeholders from all sectors grapple with these emerging issues, the legal and business communities will play a pivotal role in shaping the future of innovation and creativity.

Follow us on socials:

• LinkedIn
• X
• YouTube

Author Bio

Christopher Klimovski is a dynamic professional, leveraging his diverse educational background encompassing a Bachelor’s degree in Medical Science and a Juris Doctorate specializing in Intellectual Property law to delve into the realms of futurism and technological disruption. With a passion for exploring the intersections of science, law, and technology, he crafts insightful analyses that illuminate the implications of cutting-edge advancements on society, industry, and beyond. Christopher’s work is characterized by its depth, clarity, and foresight, as he navigates complex ethical and legal landscapes to offer readers a glimpse into the possibilities and challenges of an ever-evolving future.

The post The People vs. AI: Who Owns Ideas in the Era of Generative Artificial Intelligence? appeared first on Patsnap.

Technological innovation is advancing at an ever-increasing pace. Over the past decade, global research and development (R&D) spending, a pivotal driver of technological innovation, has grown from 2.00% of GDP to 2.63%. After over a century of combined effort, 100 million patents were filed as of 2017, serving as the legal proof of technological innovation. This number is expected to double within the next ten years. While the realm of innovation encompasses a wide array of individuals, organizations, and institutions, it is undeniable that a significant portion of groundbreaking innovations can be attributed to a select group of tech companies.

Patsnap releases our very first Global Innovation Report, to identify and celebrate these innovation frontrunners, built on our proprietary “Innovation Capability Evaluation Model”. We identify and celebrate both the world’s top innovators, the Global Innovation 100, who have consistently pushed the boundaries of technology, and the rising Global Disruption 50, young companies who have developed remarkable technology capabilities, bringing disruptive change to the world. These global innovators and disruptors together represent the dynamic landscape of innovation, shaping the future of technology across a diverse array of industries.

Beyond the identification of these companies, we also illustrate some insights into the essence of their innovation. The Global Innovation 100 and Global Disruption 50 are not just 150 individual companies, each of them represents a small innovation ecosystem as there can be hundreds of subsidiaries within each organization. Together they represent the dynamic landscape of innovation, shaping the future of technology across a diverse array of industries.

Jump to…

Who are the 2023 Global Innovation 100?

Who are the 2023 Global Disruption 50?

Innovation is Deeply Interconnected

Methodology Behind the Report

Who are the 2023 Global Innovation 100?

The Global Innovation 100 are the greatest innovators of this era. Over the years, they have led the world’s technology progress, and consistently outperform others in technology innovation.  They are also trailblazers in the innovation ecosystem. They exert a profound influence on companies both within and beyond their respective industries, propelling the advancement of our times.

In the 2023 list, the 100 tech giants demonstrate distinctive capability in all the four technology dimensions. They have a huge technology size with outstanding technology quality, radiating profound technology influence, and a high degree of technology globalization.

Each company also has its own technology characteristics. For example, Samsung Electronics has the largest technology size, who filed a total of 884K patents. Johnson & Johnson outperforms all the others in terms of technology influence, whose patents are totally cited at 6.6M times high. In terms of technology globalization, Huawei has 64K PCT patent filings, and Pfizer’s patents cover a staggering 138 countries and regions – both are top among the 100 companies.

The Global Innovation 100 contribute to a quarter of the World’s technology innovation. Together, they are holding 3.58M valid inventions, which accounts for 22% of the world’s total technology assets. While in terms of technology globalization, they totally filed 1.27M PCT patents, indicating a 27% presence in the international technology competition. Most important of all, their patents are cited 153M total times, contributing to as much as 35% of the world’s technology inspiration. Despite these impressive innovation numbers, these 100 companies, alongside with their 68K tech subsidiaries, they account for less than 2% of the world’s total number of tech companies.

The Global Innovation 100 come from a variety of regions and industries. These top innovators come from 11 industries, 70% of them falling in Life Science & Healthcare, Chemicals & Materials, Electronics and Machinery & Equipment. Among them, Asian companies has a higher percentage in Chemical & Materials, Electronics and Machinery & Equipment, while their American and European counterparts have particularly strong presence in Life Science & Healthcare. In terms of geographical distribution, they come from 15 countries/regions. But in terms of patent applications, their technology footprints spread over the world.

Although showing signs of a slowing pace of innovation, the Global Innovation 100 are taking active steps to develop cutting-edge technologies. They have an average technology growth rate of -2.3% over recent years, slightly lower than overall global technology growth and economic growth. Only one in five of the 100 companies listed has maintained positive growth. But they are also gaining strong growth on some cutting-edge fields, such as smart grids and biomedical engineering. These “high-growth” tech subsidiaries are mainly concentrated in Asia and the U.S.. Both in-house incubation and external acquisition are used to build their portfolios.

Who are the 2023 Global Disruption 50?

The Global Disruption 50 are highly ambitious companies that demonstrate disruptive innovation capabilities and keep growing fast. They often lead to awe-inspiring breakthroughs and bring about disruptive changes in the established world, inspiring new possibilities. They have the potential to become future Global Innovation 100 members. We use our proprietary Model to select those top performers, with important restrictions of being “young” and “active”.

In the 2023 list, we see those young pursuers demonstrate vigorous ambition and significant progress. Founded between 2009-2019, these organizations have built up an astonishing technology competitiveness in less than 15 years. They also exhibit a high growth rate with an average patent application CAGR of 51%. 

Despite their relatively modest size and limited global coverage, these organizations are already showcasing a potent technological influence. A typical Disruption 50 company has only about 3600 patent applications, 2% of the size of an Innovation 100 company. They are also far less globalized, since their technologies only touch averagely 19 countries or regions, merely 1/4 of the average of Innovation 100. However, each of its patents receive 8.3 citations, almost equal to that of a Global Innovation 100 company. Top technology influencers include Snap, Kioxia, Cerence, Stripe etc., whose top 10 cited patents are cited 300-600 times on the average.

The Global Disruption 50 companies mostly come from the U.S. and China. The U.S. maintains a dominant position, accounting for half of the list. And most of them are focusing on Information Technology and Life Science & Healthcare. China is rapidly advancing with 20 companies, particularly in High-Tech Manufacturing, a strong contrast to its relatively weak presence in Global Innovation 100. Other 5 companies come from Japan, Australia, U.K., Ireland and Netherlands, one in each country.

From the Global Innovation 100 to the Global Disruption 50, the world’s innovation is shifting from a physical “world of Atoms”, to a digital “world of Bits”, and even a “world of Atoms empowered by Bits”. Nearly 30% of the Global Disruption 50 companies are from the IT domain. While DoorDash provides online food delivery services in the U.S., Lyft provides online shared transport services. And Zoom is reinventing the conventional teleconference with revolutionary online tools. Many participants from other industries are also offering solutions integrating physical products and digital services. For example, Peloton Interactive is a game-changer in the fitness sector providing workout equipment as well as software and platforms. Pateo is the end-to-end solution provider for the Internet of vehicles from automotive electronics and software to operating systems.

Innovation is Deeply Interconnected

The abundant tech data behind the Global Innovation 100 and Global Disruption 50 also sheds light on the overall landscape of innovation. We can clearly see that innovation is deeply interconnected.

Innovation collaboration is Ubiquitous. The Global Innovation 100 collaborate closely with each other in R&D. 99 out of the Global Innovation 100 participants have collaborated on technology innovation with others from the list. And each global innovative leader has averagely 26 partners in the list. Jointly, they have filed a staggering 85K patents. Those with the most partners are Panasonic, Siemens and Hitachi, each with around 50 partners. While those with the most joint patent applications are Toyota, Denso and Hitachi, each with more than 10K joint patent applications.

Interestingly, these tech giants also demonstrate different collaboration preferences. The U.S.’s 36 companies among Global Innovation 100 are more inclined to file joint patent applications with their overseas counterparts. Their joint patent applications with domestic counterparts are 40% of that with overseas counterparts. By contrast, the Japanese ones prefer cooperating with domestic counterparts, their joint patent applications with domestic counterparts being 6 times that of overseas ones. When we take a closer look at the top 10 technology partners of Global Innovation 100, 9 pairs out of 10 are from Japan. The top pair are Toyota and Denso. Denso, as a former subsidiary of Toyota, continues to technologically cooperate with Toyota after its spinoff. The 2 companies have jointly filed as many as 13K patent applications with each other. Additionally, Toyota Motor and Sumitomo Electric have more than 2K joint patent applications, and so do NEC and Fujitsu. Only 1 pair is from the U.S, namely, Abbott and AbbVie, who have jointly filed 1.2K patent applications.

The Global Disruption 50 participants also have strong relationship with the Global Innovation 100. 5 out of the 50 companies are spinoff from other well-established tech giants, some of which are even among the Innovation 100. For example, Resideo and Advansix are both spin-offs from Honeywell, one of the 2023 Global Innovation 100 companies. Kioxia, the Japanese semiconductor leader, inherited the core semiconductor technology of nearly 20K patents from its former parent company Toshiba, who is also one of this year’s Global Innovation 100. With the “legacies” they have inherited from their former owners, these companies have obtained unique technology advantages from day one, and they continue to make technology breakthroughs.

Methodology Behind the Report

Patsnap’s annual Global innovation report is constructed based on Company Innovation Capability Evaluation Model. The model includes 1+4 dimensions, namely, 1 enterprise competitiveness dimension and 4 technology dimensions, i.e., Technology Size, Technology Quality, Technology Influence and Technology globalization. Integrating all the 40+ indicators up, each tech company has a final score of innovation capability.

Based on the model, we keep evaluating innovation capability of the ~100 million tech companies all over the world, as well as their comprehensive innovation metrics, with a complex calculation of the ~180 million patents behind them.

In the report, we use the model to select the top performers as this year’s “Global Innovation 100”. And for “Global Disruption 50”, we keep the top performance as the core criteria, while adding 2 restrictive conditions of being “young” and “active”: they should be less than 15 years since founding, and their patent growth in past 3 years should have an annual growth rate of at least 10%.

It should be noted that all the companies listed are independent, not subsidiaries of any other company.

Enhance your understanding of global innovation by delving into the full report.

The post Patsnap Releases 2023 Global Innovation Report: The Brilliant Names to the Dynamic Landscape of Innovation appeared first on Patsnap.

Rapid Evolution and Ambitious Growth:

Formation and Growth:

Emerging within the last 15 years, the Global Disruption 50 participants are dynamic entities rapidly cultivating remarkable technological capabilities. Unlike the established giants of the Global Innovation 100, these disruptors, on average, are around 15 years old and boast an impressive growth rate of approximately 50% per year, outpacing both global averages and the slower-growing or stagnating Global Innovation 100.

Innovation Profile:

A typical “innovation profile” of a 2023 Global Disruption 50 company is characterized by a medium technology size, averaging around 3,600 patent applications. Their technology quality is solid, reflected in an invention application percentage of 87%. Despite limited technology globalization, with patents applied for in only 19 countries/regions on average, these disruptors exhibit a strong technology influence, with each patent cited more than 8 times on average.

Comparative Analysis with Global Innovation 100:

Technological Impact:

Despite a relatively modest size and limited global coverage, the 2023 Global Disruption 50 are already demonstrating a potent technological influence, instigating profound transformations across the world. Their technology quality and influence almost match those of the established Global Innovation 100, showcasing the disruptive potential within their compact portfolios.

Invention Application Percentage:

A typical Disruption 50 company boasts an invention application percentage of 87%, aligning closely with an Innovation 100 company’s 91%, highlighting a similar commitment to high-quality innovation.

Patent Citations:

The average number of patent citations for a Disruption 50 company stands at 8.3 times, closely paralleling the Global Innovation 100’s 8.6 times. This similarity underscores the impactful nature of the disruptive technologies being developed by the rising stars.

Technological Globalization:

While the Global Disruption 50 are less technologically globalized compared to their Innovation 100 counterparts, with patents covering only 1/4th the geographic range, their focused influence is already triggering transformative shifts in targeted regions.

Visual Insights into Disruption:

The report is enriched with graphical representations, offering intuitive insights into the disruptive capabilities of the 2023 Global Disruption 50, highlighting their unique strengths and impact on the global technological landscape.

The Patsnap 2023 Global Disruption 50, though relatively nascent in their journey, are proving to be dynamic forces of innovation. With their ambitious growth, solid technological capabilities, and impactful influence, these disruptors are reshaping the innovation narrative. For a comprehensive analysis and deeper insights, explore our 2023 Global Innovation Report and witness the disruptive potential that is redefining the future of innovation.

The post Patsnap’s 2023 Disruption 50: A Closer Look at Tomorrow’s Innovators appeared first on Patsnap.

Jump to…

What is Tirzepatide?

An Overview View of Tirzepatide’s Top 10 Patent Assignees 

Evolution of the Competitive Landscape

Access Comprehensive Data on Tirzepatide Sequence Patents for Free 

What is Tirzepatide?

Mounjaro (tirzepatide) is a dual agonist for glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It was approved by the US FDA in May 2022 for use in combination with diet and exercise to improve glycemic control in adults with type 2 diabetes. According to the press release of Eli Lily, Mounjaro represents the first new type of diabetes medication in nearly a decade. 

A similar drug that’s recently gained popularity, Semaglutide (marketed as Ozempic) was approved by the US FDA in 2017 for the control of blood glucose in patients with type 2 diabetes. Semaglutide is a GLP-1 receptor agonist that stimulates the production of insulin and inhibits the secretion of glucagon, thereby reducing appetite and food intake. In June 2021, semaglutide injection (once weekly, 2.4 mg), marketed as Wegovy, was approved by the FDA for the first time for the treatment of obesity. This marked the first new weight loss medication approved by the FDA since 2014. 

An Overview View of Tirzepatide’s Top 10 Patent Assignees 

According to the Patsnap Bio Sequence Database, the top 10 applicants for the Tirzepatide patent are as follows:  

• Eli Lilly with 101 applications 
• Sun Pharmaceutical with 14 applications, and  
• Applied Molecular Transport with 8 applications.  

For more applicants, please refer to the image below. 

Source, Patsnap Bio 

Evolution of the Competitive Landscape

Exploring the changes occurring within the application structure amongst tirzepatide’s top 10 patent assignees over time delivers insights into the competitive landscape’s evolution. 

Source, Patsnap Bio 

Access Comprehensive Data on Tirzepatide Sequence Patents for Free 

First, create a free account with Patsnap Bio Sequence Database. Then, navigate to the homepage’s “standard search” and enter the Tirzepatide sequence or simply input the drug name, Tirzepatide, in the “Drug/Gene index.” This step will uncover extensive information about Tirzepatide’s sequence, patent, literature, data from diversified sources, and visual representations of the competitive landscape of patents. 

The left panel of the search results page is equipped with an array of filters that allow you to pinpoint specific data to enhance your search experience and overall efficiency. Clicking on each data point will reveal a comprehensive dataset and a host of practical tools to support your research.  

Patsnap Bio is the most extensive sequence search platform for the Patsnap database. It incorporates AI with human-curated data for comprehensive handling of protein and nucleotide sequence data plucked from global patents, biological periodicals, and public repositories. Essential biological sequences are manually annotated to highlight structural modifications to provide the most accurate sequence data and speed up the efficiency of sequence retrievals. 

To get started, create an account today. Registration is free, so you have nothing to lose and so much insight to gain: https://bio.patsnap.com.

The post The Evolution of Tirzepatide’s Competitive Landscape   appeared first on Patsnap.

Overcoming these hurdles is no easy task, and why 96% of drugs never make it to market. But the tide is changing. Research that previously took years to complete can now be done in a matter of days or weeks. Technological advancements in AI and machine learning make it faster and more efficient for scientific researchers to identify antibodies, validate targets, and analyze chemical structures and unfamiliar sequences.  

In this article, we’ll explore how to use Patsnap’s Bio Sequence Database to explore the functionality and applicability of unknown sequences. To illustrate this process, we’ll take a closer look at AAV (adeno-associated virus) drug development, serving as a tangible example of how sequence exploration can be achieved. 

Jump to . . .

• What are AAVs? 
• What is AAV Drug Development? 
• How Does Patsnap Bio Accelerate Scientific R&D? 
• About Patsnap Bio

What are AAVs?

Adeno-associated viruses, commonly referred to as AAVs, are a class of small, non-enveloped viruses that have gained significant attention in the field of biotechnology and gene therapy. These viruses belong to the Parvoviridae family and are characterized by their ability to infect both dividing and non-dividing cells, making them particularly appealing vectors for delivering genetic material into host cells. 

AAVs are naturally occurring in humans and other animals, and they are generally considered non-pathogenic, meaning they do not cause significant disease in their natural state. This safety profile has made them a popular choice for gene therapy applications. 

Researchers have harnessed the unique properties of AAVs to develop a versatile platform for delivering therapeutic genes into target cells. By engineering these viruses to carry specific genetic payloads, scientists can use AAVs to replace or correct faulty genes, introduce therapeutic proteins, or modulate cellular functions. This approach holds tremendous promise for the treatment of a wide range of genetic disorders, including inherited diseases and genetic mutations responsible for various medical conditions. 

What is AAV Drug Development? 

Imagine AAVs as tiny “drug delivery trucks” at the molecular level. Scientists modify these AAVs to carry genetic instructions or therapeutic molecules to target cells within the body. Once these AAVs reach their destination, they release their cargo, which can include instructions to produce a beneficial protein, fix a genetic defect, or regulate cellular processes. 

AAV drug development has shown great promise in treating a wide range of medical conditions, especially genetic disorders. For example, in cases where a person has a faulty or missing gene that causes a disease, AAVs can be programmed to carry a corrected version of that gene and deliver it to the affected cells. This approach has the potential to provide long-lasting relief or even a cure for genetic diseases. 

AAVs can also be used to deliver therapeutic proteins directly to specific tissues or organs, making them a versatile tool for developing treatments for various diseases, including those that affect the nervous system, muscles, and organs. 

How Does Patsnap Bio Accelerate Scientific R&D? 

Now let’s explore how to use Patsnap’s AI-powered Bio platform to extract the insights you need for more efficient R&D. We’ll use the example of AAVs.  

Within our Bio database, the first step is straightforward — simply input the raw AAV9 sequence and apply filters to search for related sequences. The image below provides an example of what you should see on your end when you run this search.  

Next, select the “View Sources” option. This will provide you with an in-depth breakdown of the listed sequences for more comprehensive analysis.

To further enhance your query, simply incorporate specific keywords and target tissues when searching through the database. Using this approach, you can quickly identify core patent sequences that streamlines scientific R&D.

About Patsnap Bio

Patsnap Bio offers the most extensive sequence search platform within Patsnap’s suite of products. Merging AI with expert-curated data, it offers an in-depth analysis of protein and nucleotide sequences sourced from global patents, biological journals, and public databases. Key biological sequences receive manual annotations, highlighting structural changes, ensuring utmost accuracy and optimizing sequence retrieval efficiency. 

To get started, create an account today. Registration is free, so you have nothing to lose and so much insight to gain! 

The post Patsnap Bio: How to Investigate Sequence Functionality & Global Development appeared first on Patsnap.

In this article, we’ll explore what target sequences and patent claims are, and explain how Patsnap helps accelerate the research process.

Let’s get started!

Jump to . . .

• What is a Target Sequence?
• What are Patent Claims?
• How Target Sequences and Patent Claims Connect
• How Patsnap Accelerates the Research Process

What is a Target Sequence?

A target sequence refers to a specific DNA, RNA, or protein sequence that a researcher or company is particularly interested in, either because of its potential applications, unique functionalities, or its value in ongoing projects.

Think of it as the “golden ticket” amidst the vast and dense world of patented sequences. Just like one would zero in on a specific chapter in a massive tome, a patent search zeroes in on a target sequence amidst the myriad of sequences stored in patent databases. This precision allows for more efficient R&D, ensuring that innovators aren’t treading already patented grounds.

What are Patent Claims?

Imagine an inventor’s blueprint, detailing the essence of their brainchild. Patent claims are akin to these blueprints. They precisely define the boundaries of an invention, laying out what it is and, just as crucially, what it is not.

These claims serve as the heart and soul of a patent, staking a clear territory in the vast intellectual property (IP) landscape. They delineate the scope of protection granted to the inventor. Just like a fortress’s boundary walls protect its treasures, patent claims safeguard an inventor’s unique ideas, ensuring no trespassers unknowingly or knowingly step onto their intellectual turf.

In essence, if patents were novels, patent claims would be their pivotal chapters, capturing the crux of the story and setting the stage for all the drama (or disputes) to unfold. So, when navigating the patent realm, understanding claims is pivotal – they’re the beacon guiding one’s journey, ensuring clarity and protection in a sea of innovation.

How Target Sequences and Patent Claims Connect

A targeted sequence in a patent search will often be the subject of one or more patent claims. These claims describe and protect the specific uses, applications, or methods related to that sequence. In other words, the patent claims offer a protective embrace to these sequences, ensuring their intellectual sanctity.

By understanding the targeted sequences within patent claims, a researcher can ascertain what specific aspects of a sequence have been previously claimed and protected. This knowledge prevents them from inadvertently infringing on existing patents. Secondly, by delving deep into these claims, a researcher can identify gaps or opportunities, potentially paving the way for novel innovations or alternative applications.

How Patsnap Accelerates the Research Process

With the Patsnap patent database and its Bio Database at your fingertips, identifying your target sequence is a breeze. Here’s a step-by-step guide to get started:

1.) Register for a free account

2.) Once registered, input the patent number (for example, ‘WO2018020476A1’), into the patent data search bar.

3.) Access the patent’s main page to see its details and check the disclosed rights in the right-claim section. Then, in the top right, select “Sequence Assistant,” input your desired sequence such as SASYRYS, and click “Search Sequence,” as illustrated in the figure below.

4.) For a clearer view, activate the “Sequence Highlight” feature on the right. Sequences that fully match will shine in red, partial matches in yellow, and other patent sequences in blue. This distinction makes it straightforward to spot your target sequence, such as “SEQ ID NO: 5”, within the claim of rights, showcasing all its positions.

Follow these four steps each time you need to quickly identify your target sequence in dense patent claims.

About Patsnap Bio

Patsnap Bio offers the most extensive sequence search platform within Patsnap’s suite of products. Merging AI with expert-curated data, it offers an in-depth analysis of protein and nucleotide sequences sourced from global patents, biological journals, and public databases. Key biological sequences receive manual annotations, highlighting structural changes, ensuring utmost accuracy and optimizing sequence retrieval efficiency.

To get started, create an account today. Registration is free, so you have nothing to lose and so much insight to gain!

The post How to Quickly Identify Your Target Sequence in Dense Patent Claims with Patsnap appeared first on Patsnap.

This report consists of four parts:

1. August new drug approvals

2. New drug analysis 

3. Global drugs under Expedited Review Pathway

4. Analysis of selected ERP drugs 

Report Overview

1.) August Drug Approvals

In August 2023, a total of nine drugs received global approval. This included three monoclonal antibodies, two bispecific antibodies, two small molecule drugs (SMDs), one RNA vaccine, and one aptamer drug conjugate.

2.) New Drug Analysis

This report features in-depth analyses of five newly approved drugs, including a thorough examination of Avacincaptad pegol.

Avacincaptad pegol treats the severe eye condition known as geographic atrophy. It aims to delay vision deterioration by preventing the immune system from damaging eye cells.

3.) Global Drugs Under Expedited Review Pathway

What’s more, 56 drugs were placed on ERP in August, including 35 orphan drug designations, nine with fast track status, four targeting rare pediatric diseases, three under breakthrough therapy designation, three with priority reviews, two receiving accelerated approvals, and one granted conditional marketing approval.

4.) Analysis of Selected ERP Drugs 

This report also highlights five ERP drugs for detailed analysis. Focusing on Savolitinib — a receptor tyrosine kinase inhibitor targeting the mesenchymal-epithelial transition factor (MET), here’s what we uncovered:

Gain Access to the Comprehensive Report for FREE – Download Now! If you aren’t registered for Synapse (registration is required to download the report), click here to register for free.

Patsnap Synapse Database: An Overview and Key Features

Discover the innovative PatSnap Synapse database – an AI-powered platform that provides intuitive interfaces, curated content, and access to massive information sources. With integrated access to company data, diseases, targets, clinical studies, and biological and chemical entities, our platform offers a powerful search and association experience. Sign up for free today and experience the benefits for yourself!

R&D Decision Makers

Our mission is to empower R&D decision makers with swift access to accurate and connected data, facilitating their understanding of emerging technology trends, competitive landscapes, and partnership opportunities. By providing comprehensive insights, our platform helps decision makers to navigate and steer the direction of innovation with confidence.

Business Development Professionals 

We offer a comprehensive database that covers the drug pipeline and investment history for over 320,000 life science organizations. This invaluable resource allows you to make informed decisions regarding potential partnerships or acquisition targets with confidence. Gain access to our extensive database and unlock the insights you need to drive your business forward.

Pharmaceutical Analyst 

Our platform is designed to accelerate the research process for pharmaceutical analysts by leveraging a wealth of connected data, including drug approvals, clinical trials, patents, non-patent literature, and news. With Synapse, users gain a comprehensive 360-degree view of the competitive and technological landscape, empowering them to make informed decisions quickly and efficiently. Discover the power of Synapse and revolutionize your research today.

Copyright Statement: This report is the sole property of Patsnap and is protected under copyright laws. Any reproduction, excerpting, or other use of this report without explicit authorization from Patsnap is strictly prohibited. Authorized products must be used within the scope of authorization and must include a clear indication of the source. Patsnap reserves the right to investigate any violations of this statement and pursue legal action as necessary. For inquiries regarding authorization, please contact phs@patsnap.com.

The post August 2023 Global Innovative Drug Report appeared first on Patsnap.

In this article, we explore what 6G technology is, why it’s essential, and how it’s poised to disrupt the communications industry.

Jump to . . .

• What is 6G?
• 6G vs. 5G: What’s the Difference?
• Why is 6G Technology Necessary?
• 6G’s Impact on End Users
• Closing Thoughts

What is 6G?

6G technology represents the sixth generation of wireless communication systems, offering faster speeds, increased capacity, and ultra-low latency compared to its predecessor, 5G.

Its goal is to establish a ubiquitous network environment, seamlessly connecting humans, devices, and machines.

6G vs 5G: What’s the Difference?

5G was first introduced in 2019, and unlike 3G and 4G before it, 5G was not just an incremental tech advancement, it was a true leapfrog technology.

One of the biggest differences between 5G and its predecessors is speed. It also used higher frequency bands allowing for much faster data transfer speeds and greater bandwidth capacity. As a result, a new world of possibilities emerged enabling applications such as autonomous vehicles, the Internet of Things (IoT), and smart cities.

6G’s anticipated features include terabits-per-second data rates, enabling seamless streaming, AR/VR/MR applications, and extensive IoT connectivity. Sustainability and energy efficiency are paramount, as 6G aims to reduce the environmental impact of wireless networks while delivering advanced connectivity.

6G is expected to use a different type of Radio access network (D-RAN, C-RAN, and Open RAN) and incorporate novel frequency bands and spectrum resources to accommodate the increasing demand for wireless communication. It could utilize the higher frequency bands, such as the terahertz (THz) range, which would enable higher data rates.

Why is 6G Technology Necessary?

The development of 6G technology arises from several factors and anticipated requirements in the ever-evolving landscape of communication networks. As technology evolves, the demand for data continues to grow exponentially in bandwidth-intensive applications such as ultra-high-definition video streaming, virtual and augmented reality, etc.

Ultimately, the development of 6G is a forward-looking approach to ensure that communication networks can keep up with evolving technology trends and meet the demands of future applications that may require unprecedented speeds, capacities, and capabilities.

6G’s Impact on End Users

6G is expected to reduce energy consumption of massive wireless
networks. It may incorporate green technologies and design
principles to minimize the environmental impact of network
infrastructure.

It aims to provide seamless connectivity not only for humans but
also for various devices and machines, forming a pervasive network
environment. Additionally, the integration of advanced technologies such
as artificial intelligence, edge computing, and advanced antenna
technologies are expected to optimize network resource allocation,
enhance security, and improve user experience.

Potential use cases of 6G technology include:

• Holographic communication
• Smart cities
• E-health and remote surgery
• Smart Transportation
• Virtual and Augmented Reality
• Internet of Automated Things

Closing Thoughts

Although 6G is currently in its early research and development phases, experts and researchers are already exploring the future requirements and potential advancements beyond 6G.

To learn more about 6G technology and how it’s poised to disrupt communication, download our report, Exploring the Revolutionary Potential of 6G Technology.

This report explores global 6G research and innovation, patent trends, top countries, and emerging players, and much more. To get the report, click here.

The post 6G Technology: The Future of Communications? appeared first on Patsnap.

California-based Alef Aeronautics is accepting preorders for its FAA-approved electric flying car. The “Model A” offers a 200-mile road range and a 110-mile flying range. Featuring a unique rotating cabin, it can vertically launch and provide a panoramic flight view.

Launching in 2025 with a $300,000 price tag, this flying car might currently be out of reach for most consumers. However, its eventual evolution for broader affordability is inevitable.

In this article, we delve into the EV and aviation trends propelling the emergence of electric flying cars.

Let’s dive in!

Jump to . . .

• What is an Electric Vehicle?
• What is a Flying Car?
• EV & Aviation Trends Paving the Way for Flying Cars
• EV Patent Filing Trends
• Electric Plane Trends
• Key and Emerging Players
• EV and Electric Aircraft Funding Trends

What is an Electric Vehicle?

An electric vehicle (EV) is a mode of transportation powered primarily by electricity, harnessed from a rechargeable battery pack. Unlike conventional vehicles that use internal combustion engines fueled by gasoline or diesel, EVs rely on electric motors for propulsion.

When in motion, these motors convert the stored electrical energy into mechanical energy. Charging an EV involves plugging it into an external electricity source, replenishing the battery for subsequent use.

What is a Flying Car?

A flying car is a hybrid vehicle that seamlessly combines the capabilities of a traditional automobile with those of an aircraft.

Designed for both road and aerial travel, flying cars aim to revolutionize urban mobility by providing a versatile solution to traffic congestion and long commute times.

Typically powered by advanced propulsion systems, often electric or hybrid-electric, these vehicles are equipped with vertical takeoff and landing (VTOL) capabilities, allowing them to ascend or descend without a runway. As the convergence of automobile and aerospace technologies continues, flying cars represent the frontier of transportation, blending the convenience of ground vehicles with the agility and speed of flight.

EV and Aviation Trends Paving the Way for Flying Cars

1.) EV Patent Filing Trends

As the graph above illustrates, patent filing trends in EV and aviation are on the rise. This is significant because the rising trend in patent filings for EVs and uncrewed vehicles indicates growing innovation and investment in these sectors, particularly over the past six years.

It suggests a shift in transportation and technological advancements — such as flying cars.

2.) Electric Plane Trends

Flying cars aren’t the only electric innovation about to hit the sky. Commercial airlines are also working to debut electric and hybrid aircraft.

The rise in electric plane patent filings, as depicted in the above chart, signals a shifting landscape in aviation, emphasizing electric propulsion. By 2025, an expected 73,000 applications in this domain highlight the industry’s commitment to electrification.

The collaboration between giants like Boeing and NASA with major airlines on the Sustainable Flight Demonstrator project emphasizes the industry’s move towards cleaner and more efficient air travel. With the innovative X-66A promising a significant reduction in fuel consumption and emissions, the trajectory is clear: the future of aviation is electric.

The success and acceptance of electric planes play a crucial role in paving the way for flying cars. If the aviation industry can successfully integrate electric planes and gain consumer trust in their safety and efficiency, it sets a precedent and opens doors for the broader adoption of flying cars. The advancements in electric flight technology, infrastructure, and regulations for electric planes will be instrumental in shaping the future of urban air mobility, including flying cars.

3.) Key and Emerging Players

Airplane titan Boeing, valued at over $136 billion, has long been a dominant force in the electric aircraft arena. Yet, what’s somewhat surprising is the entrance of tech powerhouse Huawei into this sector in 2017.

Looking at top innovators in the EV arena, we also see a similar pattern with Huawei:

Huawei’s rapid ascent as a leading innovator signifies a blurring of industry boundaries and hints at a future where tech giants could reshape the aviation landscape.

4.) EV and Electric Aircraft Funding Trends

To truly grasp the dynamics of an industry, it’s imperative to trace the financial trends. When it comes to EVs and electric aircraft, 2021 marked a significant peak in investments.

Funding for electric aircraft reached nearly $4B, while EVs garnered just under $78B.

However, there was a noticeable decline in 2022, but the investments appear to be experiencing another uptick this year.

This financial ebb and flow not only underscores the industries’ vitality and resilience but also emphasizes the unwavering investor confidence in the future of electric transportation.

Closing Thoughts

Alef Aeronautics’ forthcoming FAA-approved electric flying car is ushering in a new era in transportation. With a surge in patent filings and tech giants like Huawei entering the scene, the future of flying cars is not just promising but imminent. Ultimately, electric innovation is driving us toward an aerial revolution.

The post The Rise of the Electric Flying Car appeared first on Patsnap.

This report offers a comprehensive overview of the latest advancements in the pharmaceutical industry and an analysis of each selected drug. It provides a snapshot of each drug and explores its R&D status, active patents, mechanisms of action, clinical trials, competitive landscape, and other pertinent factors.

The report consists of four parts: 

1. First Approved Drugs in July 

2. New Drug Analysis 

3. Global Drugs under Expedited Review Pathway in July 

4. Analysis of Selected ERP Drugs 

Global Innovative Drug Report Overview 

1.) First Approved Drugs in July 

In July 2023, four drugs received global approval: a prophylactic vaccine, a small molecule drug (SMD), a monoclonal antibody, and a herbal medicine.

2.) New Drug Analysis

This report highlights two recently approved drugs, with a spotlight on CYFENDUS.

3.) Global Drugs Under Expedited Review Pathway in July 

In July 2023, a total of 41 drugs globally were on Expedited Review tracks. This includes 19 with Orphan Drug designations, eight designated as Breakthrough Therapies, seven on the Fast Track, four under Priority Review, two with Conditional Marketing Approvals, two targeting Rare Pediatric Diseases, and one as a Qualified Infectious Disease Product.

4.) Analysis of Selected ERP Drugs 

In this report, we’ve chosen to analyze seven drugs from the Expedited Review Pathway. Specifically, for Zenocutuzumab, the report explores the following aspects:

Gain Access to the Comprehensive Report for FREE – Download Now! If you aren’t registered for Synapse (registration is required to download the report), click here to register for free.

Patsnap Synapse Database: An Overview and Key Features

Discover the innovative PatSnap Synapse database – an AI-powered platform that provides intuitive interfaces, curated content, and access to massive information sources. With integrated access to company data, diseases, targets, clinical studies, and biological and chemical entities, our platform offers a powerful search and association experience. Sign up for free today and experience the benefits for yourself!

R&D Decision Makers

Our mission is to empower R&D decision makers with swift access to accurate and connected data, facilitating their understanding of emerging technology trends, competitive landscapes, and partnership opportunities. By providing comprehensive insights, our platform helps decision makers to navigate and steer the direction of innovation with confidence.

Business Development Professionals 

We offer a comprehensive database that covers the drug pipeline and investment history for over 320,000 life science organizations. This invaluable resource allows you to make informed decisions regarding potential partnerships or acquisition targets with confidence. Gain access to our extensive database and unlock the insights you need to drive your business forward.

Pharmaceutical Analyst 

Our platform is designed to accelerate the research process for pharmaceutical analysts by leveraging a wealth of connected data, including drug approvals, clinical trials, patents, non-patent literature, and news. With Synapse, users gain a comprehensive 360-degree view of the competitive and technological landscape, empowering them to make informed decisions quickly and efficiently. Discover the power of Synapse and revolutionize your research today.

Copyright Statement: This report is the sole property of Patsnap and is protected under copyright laws. Any reproduction, excerpting, or other use of this report without explicit authorization from Patsnap is strictly prohibited. Authorized products must be used within the scope of authorization and must include a clear indication of the source. Patsnap reserves the right to investigate any violations of this statement and pursue legal action as necessary. For inquiries regarding authorization, please contact phs@patsnap.com.

The post July 2023 Global Innovative Drug Report  appeared first on Patsnap.